What is B. Riley’s Forecast for AVBP Q3 Earnings?

ArriVent BioPharma, Inc. (NASDAQ:AVBP) – Research analysts at B. Riley issued their Q3 2025 earnings per share estimates for ArriVent BioPharma in a research report issued on Monday, August 25th. B. Riley analyst M. Mamtani anticipates that the company will post earnings of ($0.80) per share for the quarter. B. Riley currently has a “Strong-Buy” rating on the stock. The consensus estimate for ArriVent BioPharma’s current full-year earnings is ($2.74) per share. B. Riley also issued estimates for ArriVent BioPharma’s Q4 2025 earnings at ($0.81) EPS, FY2025 earnings at ($4.30) EPS, FY2026 earnings at ($4.02) EPS, FY2027 earnings at ($3.36) EPS, FY2028 earnings at ($1.50) EPS and FY2029 earnings at $1.04 EPS.

Several other brokerages have also issued reports on AVBP. Wall Street Zen lowered ArriVent BioPharma from a “hold” rating to a “strong sell” rating in a research report on Thursday, May 22nd. Guggenheim restated a “buy” rating and set a $45.00 price objective on shares of ArriVent BioPharma in a research report on Tuesday, June 24th. Oppenheimer reiterated an “outperform” rating and issued a $44.00 target price (up from $39.00) on shares of ArriVent BioPharma in a report on Tuesday, June 24th. Citigroup reissued a “buy” rating and set a $33.00 target price (down previously from $40.00) on shares of ArriVent BioPharma in a research report on Tuesday, August 12th. Finally, HC Wainwright restated a “buy” rating and set a $42.00 price target (up previously from $40.00) on shares of ArriVent BioPharma in a report on Tuesday, August 12th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $39.14.

ArriVent BioPharma Stock Performance

AVBP stock opened at $19.21 on Thursday. The company has a market capitalization of $779.35 million, a P/E ratio of -4.78 and a beta of 1.17. The company has a fifty day moving average price of $20.65 and a 200-day moving average price of $21.06. ArriVent BioPharma has a 52-week low of $15.47 and a 52-week high of $36.37.

ArriVent BioPharma (NASDAQ:AVBP) last posted its earnings results on Monday, August 11th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.20).

Hedge Funds Weigh In On ArriVent BioPharma

Institutional investors and hedge funds have recently modified their holdings of the business. Tower Research Capital LLC TRC increased its stake in shares of ArriVent BioPharma by 773.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,599 shares of the company’s stock valued at $43,000 after acquiring an additional 1,416 shares in the last quarter. BNP Paribas Financial Markets grew its holdings in ArriVent BioPharma by 31.0% in the second quarter. BNP Paribas Financial Markets now owns 2,571 shares of the company’s stock worth $56,000 after purchasing an additional 609 shares during the period. Tower Research Capital LLC TRC increased its stake in ArriVent BioPharma by 571.6% in the second quarter. Tower Research Capital LLC TRC now owns 6,669 shares of the company’s stock valued at $145,000 after purchasing an additional 5,676 shares in the last quarter. Jane Street Group LLC bought a new stake in ArriVent BioPharma in the first quarter valued at $189,000. Finally, Walleye Capital LLC acquired a new position in shares of ArriVent BioPharma during the second quarter valued at about $206,000. 9.48% of the stock is currently owned by institutional investors.

About ArriVent BioPharma

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.